Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:41 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 7,081 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Terminated Phase 2 Interventional Results available

Lonafarnib in Metastatic Breast Cancer

NCT00773474
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lonafarnib
Drug
Lead sponsor
George Sledge
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Galesburg, Illinois • Bloomington, Indiana • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Nov 3, 2026, 2:41 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Bexa Breast Examination

NCT06643767
View directory record Official record
Conditions
Breast Cancer
Interventions
Bexa and focus ultrasound
Device
Lead sponsor
Sure, Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Nov 3, 2026, 2:41 AM EST
Terminated Phase 2 Interventional Results available

Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer

NCT01937507
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
HAI with FOLFOX
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Nov 3, 2026, 2:41 AM EST
Completed Phase 1 Interventional

Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors

NCT00096707
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer
Interventions
2-deoxy-D-glucose (2DG)
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
3
States / cities
Miami, Florida • Indianapolis, Indiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Nov 3, 2026, 2:41 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms

NCT03706534
View directory record Official record
Conditions
Breast Cancer, Breast Lesions, Breast Mass
Interventions
Ultrasound Image review with CADe, Ultrasound Image review with CADx, Ultrasound Image manual review, Biopsy
Device · Procedure
Lead sponsor
Samsung Medison
Industry
Eligibility
19 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Nov 3, 2026, 2:41 AM EST
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211
View directory record Official record
Conditions
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Nov 3, 2026, 2:41 AM EST
Completed No phase listed Observational

Studying Normal Breast Tissue and Cancer Risk

NCT00341692
View directory record Official record
Conditions
Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Skin Diseases
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
11 Years to 120 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Nov 3, 2026, 2:41 AM EST
Not listed Not applicable Interventional

The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy

NCT01071109
View directory record Official record
Conditions
Breast Cancer, Fatigue, Insomnia
Interventions
Therapeutic Massage
Procedure
Lead sponsor
Floyd Memorial Hospital and Health Services
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Albany, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 19, 2010 · Synced Nov 3, 2026, 2:41 AM EST
Completed Phase 3 Interventional

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

NCT00002836
View directory record Official record
Conditions
Breast Cancer
Interventions
Filgrastim (G-CSF), Carmustine, Cisplatin, Cyclophosphamide (CTX), Etoposide, Thiotepa, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Nov 3, 2026, 2:41 AM EST
Completed No phase listed Observational

Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging

NCT01027767
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Nov 3, 2026, 2:41 AM EST
Terminated Not applicable Interventional

Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome

NCT04508764
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer, Lynch Syndrome
Interventions
Families Accelerating Cascade Testing Toolkit
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Nov 3, 2026, 2:41 AM EST
Completed Not applicable Interventional

Yoga for Symptoms of Nerve Damage Caused by Chemotherapy

NCT03292328
View directory record Official record
Conditions
Breast Cancer, Peripheral Neuropathy, Gynecologic Cancer
Interventions
Yoga, Wait List Control
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Nov 3, 2026, 2:41 AM EST
Completed Phase 2 Interventional Results available

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

NCT00365365
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin and cyclophosphamide (AC) + bevacizumab, Docetaxel (T) + bevacizumab, Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab, Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab, Bevacizumab and trastuzumab maintenance therapy, Bevacizumab maintenance therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Nov 3, 2026, 2:41 AM EST
Terminated Not applicable Interventional

Vapocoolant Analgesia for Breast Lymphoscintigraphy

NCT05744557
View directory record Official record
Conditions
Breast Cancer
Interventions
num Vapocoolant
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Nov 3, 2026, 2:41 AM EST
Completed Phase 2 Interventional Results available

A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

NCT00077857
View directory record Official record
Conditions
Breast Cancer
Interventions
capecitabine (Xeloda®), docetaxel (Taxotere®)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
43
States / cities
Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Nov 3, 2026, 2:41 AM EST
Completed Phase 2 Interventional

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

NCT00002475
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer
Interventions
allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa, recombinant interferon gamma, sargramostim, cyclophosphamide
Biological · Drug
Lead sponsor
St. Vincent Medical Center - Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Nov 3, 2026, 2:41 AM EST
Active, not recruiting No phase listed Observational Results available

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

NCT03939481
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage I Ovarian Cancer AJCC v8, Stage IA Ovarian Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage IB Ovarian Cancer AJCC v8, Stage IC Ovarian Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIA Ovarian Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIB Ovarian Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8
Interventions
Chemotherapy, Functional Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
166
States / cities
Antioch, California • Dublin, California • Fremont, California + 132 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 3, 2026, 2:41 AM EST
Completed Not applicable Interventional Results available

Wrist Cooling for Hot Flashes Clinical Trial

NCT05595213
View directory record Official record
Conditions
Hot Flashes
Interventions
Active cooling device with cooling plate, Placebo device without cooling plate, Hot Flash Diary
Device · Other
Lead sponsor
Boston University
Other
Eligibility
21 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Nov 3, 2026, 2:41 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Physician Use of Non-English Language Skills in Cancer Care

NCT02726360
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Lung Cancer
Interventions
survey, Audio record
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
5
States / cities
Jamaica, New York • New York, New York • Queens, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Nov 3, 2026, 2:41 AM EST
Not listed Phase 2 Interventional

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

NCT03567720
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
tavokinogene telseplasmid, Pembrolizumab, Immunopulse, nab paclitaxel, gemcitabine plus carboplatin
Biological · Device · Drug
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
10
States / cities
Tucson, Arizona • La Jolla, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Nov 3, 2026, 2:41 AM EST
Terminated Phase 2 Interventional Results available

Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer

NCT02360059
View directory record Official record
Conditions
Breast Cancer
Interventions
Metformin, Placebo, Questionnaires, Sensory and Fine-Motor Tests
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 74 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Nov 3, 2026, 2:41 AM EST
Active, not recruiting Phase 2 Interventional

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

NCT05645380
View directory record Official record
Conditions
Triple Negative Breast Cancer, Breast Cancer
Interventions
Carboplatin, Docetaxel, Doxorubicin, Cyclophosphamide, Pembrolizumab
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 3, 2026, 2:41 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

NCT05625659
View directory record Official record
Conditions
Breast Cancer
Interventions
Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)
Diagnostic Test
Lead sponsor
American College of Radiology
Other
Eligibility
45 Years to 74 Years · Female only
Enrollment
2,032 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Boca Raton, Florida • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 2:41 AM EST
Not listed Not applicable Interventional

Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)

NCT01295723
View directory record Official record
Conditions
Invasive Lobular and Ductal Carcinoma
Interventions
Hypofractionated Whole Breast Radiation Therapy, Intraoperative Electron Radiation Therapy
Radiation
Lead sponsor
St. Joseph Hospital of Orange
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Nov 3, 2026, 2:41 AM EST